Evidence map›Paper›PMID 42322528›Full record

ReviewDrugs2026

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Bhupendra Raj Giri, Jamie Erin Spahn, Rawidh Alsaidalani, Beatriz Behrend-Keim, Mohammed Bhia, Jailen Haley Doyle, Matthew Joseph Herpin, Rex Corbin Moore, Nila Sangeetha Murali, Arifenur Safak and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bhupendra Raj GiriDivision of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, PHR 4.214, Austin, TX, 78712, USA.ORCID http://orcid.org/0000-0003-4711-8279
Jamie Erin Spahn, Via Therapeutics, Austin, TX, USA.ORCID http://orcid.org/0000-0001-8521-0047
Rawidh AlsaidalaniDivision of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, PHR 4.214, Austin, TX, 78712, USA.ORCID http://orcid.org/0000-0001-6562-690X
Beatriz Behrend-KeimDivision of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, PHR 4.214, Austin, TX, 78712, USA.ORCID http://orcid.org/0000-0002-4589-5368
Mohammed BhiaDivision of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, PHR 4.214, Austin, TX, 78712, USA.
Jailen Haley DoyleDivision of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, PHR 4.214, Austin, TX, 78712, USA.ORCID http://orcid.org/0000-0002-2920-2381
Matthew Joseph HerpinDivision of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, PHR 4.214, Austin, TX, 78712, USA.ORCID http://orcid.org/0000-0001-9734-742X
Rex Corbin MooreDivision of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, PHR 4.214, Austin, TX, 78712, USA.ORCID http://orcid.org/0009-0002-7631-1967
Nila Sangeetha MuraliDivision of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, PHR 4.214, Austin, TX, 78712, USA.ORCID http://orcid.org/0000-0002-4613-5782
Arifenur SafakDivision of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, PHR 4.214, Austin, TX, 78712, USA.ORCID http://orcid.org/0000-0002-5512-5367
Hugh David Charles SmythDivision of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, PHR 4.214, Austin, TX, 78712, USA. hugh.smyth@austin.utexas.edu.ORCID http://orcid.org/0000-0002-6582-5869

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhaled biologics to treat lung diseases have an extensive history. This is counterbalanced by the limited products that have reached the commercialization stage of development despite the numerous disease states and targets that may be suitable for the delivery of proteins, peptides, or nucleic acid therapeutics. These opportunities are reviewed alongside current and past clinical and preclinical studies that highlight both successful and discontinued programs, providing key lessons for future development. Although there are physical, biological, and technical barriers that must be overcome to successfully deliver these relatively fragile moieties to the lung, there are commercial and clinical reasons why success has not always been realized. This review captures the current landscape of inhaled biologics, and as the field advances, we expect the inhaled route to expand rapidly given its distinct pharmacokinetic advantages for local lung diseases.

Indexed as

Biological ProductsLung DiseasesRespiratory Tract DiseasesAdministration, InhalationAnimalsDrug DevelopmentHumansBiological Products

Identifiers

PMID42322528
PMCPMC13375692

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.